Travere Therapeutics (TVTX) Stock Forecast & Price Target

$17.18 -0.22 (-1.26%)

(As of 12/20/2024 05:16 PM ET)

Travere Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
1

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Travere Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a hold rating, and 11 have given a buy rating for TVTX.

Consensus Price Target

$23.67
37.76% Upside

According to the 12 analysts' twelve-month price targets for Travere Therapeutics, the average price target is $23.67. The highest price target for TVTX is $41.00, while the lowest price target for TVTX is $18.00. The average price target represents a forecasted upside of 37.76% from the current price of $17.18.

Get the Latest News and Ratings for TVTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors.

TVTX Analyst Ratings Over Time

Type	Current Forecast 12/24/23 to 12/23/24	1 Month Ago 11/24/23 to 11/23/24	3 Months Ago 9/25/23 to 9/24/24	1 Year Ago 12/24/22 to 12/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$23.67	$22.62	$17.91	$17.85
Forecasted Upside	37.76% Upside	23.92% Upside	23.00% Upside	96.98% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

TVTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Travere Therapeutics Stock vs. The Competition

Type	Travere Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	37.76% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent TVTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$12.00 ➝ $22.00	+19.70%
11/1/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $27.00	+51.26%
11/1/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$18.00 ➝ $20.00	+7.76%
10/21/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$9.00 ➝ $27.00	+51.09%
10/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$18.00 ➝ $20.00	+15.54%
10/9/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$23.00 ➝ $41.00	+140.19%
Get the Latest News and Ratings for TVTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
10/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$17.00 ➝ $25.00	+50.06%
10/8/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+31.06%
9/30/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$23.00 ➝ $22.00	+58.50%
9/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$23.00 ➝ $19.00	+32.13%
9/27/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$23.00 ➝ $18.00	+19.68%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$20.00 ➝ $23.00	+72.16%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$8.00 ➝ $10.00	+17.10%
9/22/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$30.00 ➝ $14.00	+89.19%
9/21/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/22/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$30.00	+82.37%
5/5/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 06:10 AM ET.

TVTX Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Travere Therapeutics is $23.67, with a high forecast of $41.00 and a low forecast of $18.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There is currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares.
: According to analysts, Travere Therapeutics's stock has a predicted upside of 37.76% based on their 12-month stock forecasts.
: Over the previous 90 days, Travere Therapeutics's stock had 1 upgrade by analysts.
: Travere Therapeutics has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Citigroup, Guggenheim, HC Wainwright, Leerink Partners, Piper Sandler, Scotiabank, Wedbush, and Wells Fargo & Company in the past 90 days.
: Analysts like Travere Therapeutics more than other "medical" companies. The consensus rating score for Travere Therapeutics is 2.92 while the average consensus rating score for "medical" companies is 2.81. Learn more on how TVTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

This page (NASDAQ:TVTX) was last updated on 12/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Stock Forecast & Price Target